Life sciences cloud solution provider Medidata posts ‘record’ Q2

New York’s digital services provider for biopharma Medidata ($MDSO) has posted what it is hailing as “record” numbers for the second quarter as it saw sales jump.

Total revenue for Q2 hit $114.6 million--a major leap of 17% when put next to its figures from last year.

Meanwhile, subscription revenue was $96.8 million, an increase 15%, as professional services reached a record $17.9 million--an upsurge of $3.7 million, or 26%, compared to last year.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

What’s been driving this growth? “Strong execution,” says its chairman and CEO Tarek Sherif. “With demand growing for Medidata CTMS, Payments, Balance and mHealth, as well as data analytics, we’re building on the success of the broadest platform in the industry, while continually delivering greater value to our clients,” he explained.

“Today, more than ever, our ability to generate sustainable, long-term growth is driven by the large opportunity created by our clients’ innovation, scientific advances and our mission of powering smarter treatments to improve healthcare. It’s clear that Medidata is becoming the strategic technology partner to a massive and important transformation in life sciences and healthcare driven by digital automation in drug development.”

Other records tumbled as well, as the company booked a record 96 new clients, including 32 from its April acquisition of medical image sharing firm Intelemage, during the second quarter.

Medidata’s client base also grew to 711 at the end of the second quarter, up 32% year over year.

The company said it was hanging on to its full year guidance of total revenue being set at around $450 to $474 million at constant currency rates.

It did however nudge up its expectations for its professional services revenue, which it now sees as topping out at $70 million, $10 million higher than it originally planned for.

The company ended up 14.6% at the close of play yesterday after posting its results.

- check out the release

Related Article:
Medidata swoops on medical imaging player Intelemage

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.